Results 171 to 180 of about 1,032,345 (337)

Anti-CNS antibodies in neurological and psychiatric disorders. [PDF]

open access: bronze, 1987
Audrius V. Plioplys   +4 more
openalex   +1 more source

Response to: Clinical Imaging Features of Sporadic and Genetic Frontotemporal Lobar Degeneration TDP‐43 A and B

open access: yes
Annals of Clinical and Translational Neurology, EarlyView.
Sergi Borrego‐Écija   +3 more
wiley   +1 more source

CSF Mitochondrial DNA: Biomarker of Body Composition and Energy Metabolism in Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Cerebrospinal fluid (CSF) cell‐free mitochondrial DNA (cf‐mtDNA) is a potential biomarker for Parkinson's disease (PD), but its clinical relevance remains unclear. We investigated associations between CSF cf‐mtDNA levels, body composition, nutritional status, and metabolic biomarkers in PD. Methods CSF cf‐mtDNA levels, defined as the
Yasuaki Mizutani   +11 more
wiley   +1 more source

Author Correction: GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models

open access: yesScientific Reports, 2022
Victoria E. Sanchez   +14 more
doaj   +1 more source

Clock-Drawing in Neurological Disorders [PDF]

open access: gold, 1989
Gerald J. Dal Pan   +3 more
openalex   +1 more source

Long COVID in People With Multiple Sclerosis and Related Disorders: A Multicenter Cross‐Sectional Study

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Managing long COVID in people with multiple sclerosis and related disorders (pwMSRD) is complex due to overlapping symptoms. To address evidence gaps, we evaluated long COVID susceptibility in pwMSRD versus controls and its associations with multi‐domain function and disability.
Chen Hu   +15 more
wiley   +1 more source

42. Study on the Brain Biopsy in Neurological Disorders of Children

open access: bronze, 1965
Hirota Horinouchi   +4 more
openalex   +2 more sources

Analysis of Soluble Interleukin‐2 Receptor as a Prognostic Biomarker in NMOSD and MOGAD

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Soluble interleukin‐2 receptor (sIL‐2R) is a biomarker for T cell activity. T cells are involved in neuromyelitis optica spectrum disorders (NMOSD) and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) pathogenesis. However, sIL‐2R has so far not been evaluated in these conditions.
Philipp Klyscz   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy